Vimian Group (VIMIAS) Stock Overview

Engages in the animal health business worldwide. More details

VIMIAS fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 18.7% below our estimate of its fair value

Earnings are forecast to grow 44.61% per year

Earnings grew by 132.6% over the past year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

VIMIAS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Vimian Group AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vimian Group
Historical stock prices
Current Share Price	SEK 40.12
52 Week High	SEK 40.12
52 Week Low	SEK 40.12
Beta	1.53
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	VIMIAS	GB Medical Equipment	GB Market
7D	0%	-1.9%	-2.5%
1Y	n/a	-3.5%	12.4%

Return vs Industry: Insufficient data to determine how VIMIAS performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how VIMIAS performed against the UK Market.

Price Volatility

Is VIMIAS's price volatile compared to industry and market?
VIMIAS volatility
VIMIAS Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.5%
Market Average Movement	5.0%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: VIMIAS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine VIMIAS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	1,200	Carl-Johan Boudrie	vimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

Vimian Group AB (publ) Fundamentals Summary

How do Vimian Group's earnings and revenue compare to its market cap?
VIMIAS fundamental statistics
Market cap	SEK 17.71b
Earnings (TTM)	SEK 255.04m
Revenue (TTM)	SEK 4.52b

69.5x

P/E Ratio

3.9x

P/S Ratio

Is VIMIAS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIMIAS income statement (TTM)
Revenue	€404.30m
Cost of Revenue	€126.40m
Gross Profit	€277.90m
Other Expenses	€255.10m
Earnings	€22.80m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 22, 2025

Earnings per share (EPS)	0.043
Gross Margin	68.74%
Net Profit Margin	5.64%
Debt/Equity Ratio	40.1%

How did VIMIAS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/08/01 15:40
End of Day Share Price	2025/06/30 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Hassan Al-Wakeel	Barclays
Blanka Porkolab	Barclays

Vimian Group AB (publ)BATS-CHIXE:VIMIAS Stock Report